ReviewJournal of advanced research2026
Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13.Frontiers in immunology · 2026Article
- Identification of prognostic biomarkers and development of a prediction model for prostate cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-related diseases exhibit an extremely high incidence among aging males, including Benign Prostatic Hyperplasia (BPH) and prostate Cancer (PCa). Prostate stem cells are critical for prostate development, adult tissue homeostasis, and injury repair, and are also considered potential cells of origin for tumorigenesis. Recent studies have demonstrated that various prostate stem cell populations serve as key drivers in both the initiation and progression of prostatic diseases, while also contributing to therapy resistance. Consequently, prostate stem cells have emerged as promising therapeutic targets for both fundamental research and clinical translational studies. AIM OF REVIEW: This review provides a comprehensive summary of the identity and characteristics of various prostate epithelial stem cells, elaborating on the cell fate and function of different prostate stem cells under both physiological and pathological conditions. Additionally, the review offers theoretical evidence linking the lineage plasticity of prostate stem cells to the drug resistance observed in prostate diseases, and critically discusses both the limitations and therapeutic potential of emerging stem cell-targeting strategies. KEY SCIENTIFIC CONCEPTS OF REVIEW: This review integrates contemporary knowledge regarding the identity and cellular plasticity of prostate stem cell subpopulations across physiological and pathological contexts, encompassing prostate development, tissue homeostasis, inflammatory responses, and oncogenesis. These stem cells demonstrate critical adaptability to microenvironmental challenges, underpinning essential functions in epithelial regeneration, neoplastic initiation, and tumor evolution. Significantly, their capacity to dynamically reprogram cellular fate trajectories has been shown to fundamentally underpin mechanisms of therapeutic evasion, fostering the emergence of treatment resistance. Collectively, these insights position the molecular targeting of prostate stem cells as a novel therapeutic paradigm for managing advanced prostate malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.